Humanin

Common side effects:

• Injection site redness or mild irritation
• Temporary localized swelling
• Mild fatigue post-administration
• Transient headaches

Rare or serious side effects:

• Unintended interactions with IGF-I signaling pathways
• Potential alterations in glucose metabolism
• Unknown long-term effects on cellular proliferation

Mitochondrial protection is the primary mechanism by which the Humanin peptide exerts its cytoprotective effects. It binds to specific intra- and extracellular receptors, including the Bax protein, to inhibit Bax-induced apoptosis and prevent the release of cytochrome c from mitochondria (Hazafa et al., 2021). Receptor-mediated signaling further amplifies Humanin benefits across various tissues. By interacting with cell surface receptors such as the CNTF receptor complex and FPRL-1, Humanin activates survival cascades like the STAT3 and ERK1/2 pathways, effectively shielding cells from stress-induced death (Matsuoka & Hashimoto, 2010).

Discovery of Humanin occurred in 2001 when researchers identified it in the surviving brain cells of Alzheimer's disease patients, marking it as the first known mitochondrial-derived peptide. This groundbreaking discovery shifted scientific focus toward the mitochondrial genome's role in producing biologically active peptides that regulate cellular survival and aging (Karachaliou & Livaniou, 2023). Clinical and regulatory milestones have since expanded to investigate Humanin's role in various systemic conditions. While it remains a research-only compound not approved by the FDA for human use, ongoing clinical trials are evaluating its diagnostic and therapeutic potential, such as its role in acute kidney injury (NCT06105229) and cardiac operations (NCT03431844).